Efficacy of a surfactant, allantoin, and benzalkonium chloride solution for onychomycosis: Preliminary results of treatment with periodic debridement

Journal of the American Podiatric Medical Association

Volumn 89, Issue 3, 1999, Pages 124-130

  Wadhams, Peter S ^a,b,c,d   Griffith, John ^f   Nikravesh, Payam ^f   Chodosh, Daniel ^e  

^a AMERICAN BOARD OF PODIATRIC SURGERY   (United States)

^b Family Practice Clinic   (United States)

^c Pacific Hospital of Long Beach   (United States)

^d S California Foot and Ankle Inst   (United States)

^e Woodward Laboratories Inc   (United States)

^f NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALLANTOIN; BENZALKONIUM; EMOLLIENT AGENT; SURFACTANT; TOPICAL ANTIINFECTIVE AGENT;

ADULT; AGED; ARTICLE; DEBRIDEMENT; FEMALE; HUMAN; MALE; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; ONYCHOMYCOSIS; SKIN DISEASE; SOLUTION AND SOLUBILITY;

ADULT; AGED; AGED, 80 AND OVER; ALLANTOIN; ANTI-INFECTIVE AGENTS, LOCAL; BENZALKONIUM COMPOUNDS; COMBINED MODALITY THERAPY; DEBRIDEMENT; EMOLLIENTS; FEMALE; FOOT DERMATOSES; HUMANS; MALE; MIDDLE AGED; ONYCHOMYCOSIS; SOLUTIONS; SURFACE-ACTIVE AGENTS;

EID: 0033092347     PISSN: 87507315     EISSN: None     Source Type: Journal    
DOI: 10.7547/87507315-89-3-124     Document Type: Article

References (28)

1. MIDGLEY G, MOORE MK, COOK JC, ET AL: Mycology of nail disorders. J Am Acad Dermatol 31: S68, 1994.
2. SUMMERBELL RC, KANE J, KRAJDEN S: Onychomycosis, tinea pedis and tinea manuum caused by non-dermatophytic filamentous fungi. Mycoses 32: 609, 1989.
3. ELEWSKI BE, HAY RJ: Update on the management of onychomycosis: highlights of the Third Annual International Summit on Cutaneous Antifungal Therapy. Clin Infect Dis 23: 305, 1996.
4. KEMNA ME, ELEWSKI BE: A U.S. epidemiologic survey of superficial fungal diseases. J Am Acad Dermatol 35: 539, 1996.
5. LUBECK DP, PATRICK DL, MCNULTY P, ET AL: Quality of life of persons with onychomycosis. Qual Life Res 2: 341, 1993.
6. SCHER RK: Onychomycosis: a significant medical disorder. J Am Acad Dermatol 35: S4, 1996.
7. DRAKE LA: Impact of onychomycosis on quality of life. JAPMA 87: 507, 1997.
8. CHREN M: A cost analysis of topical drug regimens for dermatophyte infections. JAMA 272: 1922, 1994.
9. ROBERTS DT: Oral therapeutic agents in fungal nail disease. J Am Acad Dermatol 31: S78, 1994.
10. JOSEPH WS: Oral treatment options for onychomycosis. JAPMA 87: 520, 1997.
11. COHEN P, SCHER RK: Topical and surgical treatment of onychomycosis. J Am Acad Dermatol 31: S74, 1994.
12. MARKINSON BC, MONTER SI, CABRERA G: Traditional approaches to treatment of onychomycosis. JAPMA 87: 551, 1997.
13. CROSS J: "Introduction to Cationic Surfactants," in Cationic Surfactants: Analytical and Biological Evaluation, ed by J Cross, EJ Singer, p 4, Marcel Dekker, New York, 1994.
14. FREDELL DL: "Biological Properties and Applications of Cationic Surfactants," in Cationic Surfactants: Analytical and Biological Evaluation, ed by J Cross, EJ Singer, p 31, Marcel Dekker, New York, 1994.
15. BOETHLING RS: "Environmental Aspects of Cationic Surfactants," in Cationic Surfactants: Analytical and Biological Evaluation, ed by J Cross, EJ Singer, p 95, Marcel Dekker, New York, 1994.
16. DROBECK HP: "Current Topics on the Toxicity of Cationic Surfactants," in Cationic Surfactants: Analytical and Biological Evaluation, ed by J Cross, EJ Singer, p 61, Marcel Dekker, New York, 1994.
17. DEPARTMENT OF HEALTH, EDUCATION AND WELFARE, FOOD AND DRUG ADMINISTRATION: "Comments on Quaternary Ammonium Compounds," in Tentative Final Monograph for Healthcare Antiseptic Drug Products; Proposed Rule (21 CFR Parts 333 and 369). Fed Regist 50: 31425, 1994.
18. CHODOSH D, INVENTOR: Antimicrobial composition of matter. US patent 5,661,170. August 26, 1997.
19. BUDAVARI S, O'NEIL MJ, SMITH A, ET AL (EDS): The Merck Index: An Encyclopedia of Chemicals, Drugs, and Biologicals, 12th Ed, p 48, Merck Research Laboratories, Whitehouse Station, NJ, 1996.
20. RUDOLPH VC, TAUSCHEL H-D: Untersuchen zur perkutanen Wirksamkeit einer Heparin-Allantoin-Dexpanthenol-Kombination in spezieller Salbengrundlage. Arzneimittelforschung 34: 1766, 1984.
21. LEMONT H: Pathologic and diagnostic considerations in onychomycosis, JAPMA 87: 498, 1997.
22. HALEY L, DANIEL CR III: "Fungal Infections," in Nails: Therapy, Diagnosis, Surgery, ed by RK Scher, CR Daniel III, p 106, WB Saunders, Philadelphia, 1990.
23. ODOM R, DANIEL CR III, ALY R: A double-blind randomized comparison of itraconazole capsules and placebo in the treatment of onychomycosis of the toenail. J Am Acad Dermatol 35: 110, 1996.
24. DRAKE LA, SHEAR NH, ARLETTE JP, ET AL: Oral terbinafine in the treatment of toenail onychomycosis: North American multicenter trial. J Am Acad Dermatol 37: 740, 1997.
25. ELEWSKI BE: Bacterial infection in a patient with onychomycosis. J Am Acad Dermatol 37: 493, 1997.
26. ZAIAS N, GLICK B, REBELL G: Diagnosing and treating onychomycosis. J Fam Pract 42: 513, 1996.
27. PIERARD GE, ARRESE-ESTRADA J, PIERARD-FRANCHIMONT C: Treatment of onychomycosis: traditional approaches. J Am Acad Dermatol 29: S41, 1993.
28. NOVARTIS PHARMACEUTICALS CORP: Document LMT-1008, Novartis Pharmaceuticals Corp, East Hanover, NJ, 1997.